11/21
04:17 am
ions
Lou Gehrig's Disease Pipeline Landscape Report 2024: Therapeutic Assessment of 80+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Low
Report
Lou Gehrig's Disease Pipeline Landscape Report 2024: Therapeutic Assessment of 80+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
11/18
11:38 am
ions
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks [Yahoo! Finance]
Low
Report
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks [Yahoo! Finance]
11/18
03:10 am
ions
ExeVir Announces Michael Garrett as New Chief Executive Officer [Yahoo! Finance]
Low
Report
ExeVir Announces Michael Garrett as New Chief Executive Officer [Yahoo! Finance]
11/14
10:12 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
11/14
08:22 am
ions
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]
Low
Report
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]
11/12
02:01 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/7
11:47 am
ions
Company News for Nov 7, 2024 [Yahoo! Finance]
Low
Report
Company News for Nov 7, 2024 [Yahoo! Finance]
11/7
10:39 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.
11/7
08:36 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Medium
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
11/7
07:05 am
ions
Ionis to present at upcoming investor conferences
Low
Report
Ionis to present at upcoming investor conferences
11/7
02:31 am
ions
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
11/6
11:24 am
ions
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
Medium
Report
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
11/6
07:07 am
ions
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome [Yahoo! Finance]
Low
Report
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome [Yahoo! Finance]
11/6
07:01 am
ions
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Low
Report
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
11/6
07:00 am
ions
Ionis reports third quarter 2024 financial results
Low
Report
Ionis reports third quarter 2024 financial results
11/4
11:14 pm
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/4
09:57 am
ions
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE [Yahoo! Finance]
Low
Report
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE [Yahoo! Finance]
11/4
09:44 am
ions
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Low
Report
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
10/31
09:17 am
ions
ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care [Yahoo! Finance]
Low
Report
ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care [Yahoo! Finance]
10/25
11:05 pm
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/23
12:08 pm
ions
Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years [Yahoo! Finance]
10/23
07:05 am
ions
Ionis to hold third quarter 2024 financial results webcast
Medium
Report
Ionis to hold third quarter 2024 financial results webcast
10/21
02:16 am
ions
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis [Yahoo! Finance]
Low
Report
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis [Yahoo! Finance]
10/21
02:08 am
ions
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
Low
Report
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
10/15
06:49 am
ions
Spotlight On SMID-Caps: Morningstar's Undervalued Picks [Seeking Alpha]
Low
Report
Spotlight On SMID-Caps: Morningstar's Undervalued Picks [Seeking Alpha]